Hemanext Inc. strengthens leadership with new board appointments

In Lexington, Pennsylvania, on May 5, 2025, Hemanext Inc., a company known for its innovative work in blood processing and storage, announced the expansion of its Board of Directors with the appointment of two experienced professionals. These individuals include Phil M Pead, who brings over 40 years of experience in the Healthcare IT and software industries, and has held significant leadership roles in various technology firms. The other newly appointed member brings a strong resume with a history of leadership in public health advisory capacities. Phil M Pead's experience also includes his tenure as Executive Director of the Presidential Advisory Council on HIV and AIDS during the George W. Bush administration and work at the FDA. Andrew Dunham, the CEO of Hemanext, expressed enthusiasm about these additions to the Board, highlighting the strengths they bring to the leadership team. Hemanext focuses on advancing technologies for the processing and storage of Red Blood Cells (RBCs), particularly through their Hemanext ONE system. This innovative system is designed to limit oxidative damage in stored RBCs and aims at improving transfusion outcomes for patients with chronic health conditions, such as thalassemia and sickle cell disease. Hemanext is committed to increasing the quality of stored RBCs and enhancing the efficacy of blood transfusion procedures, further aiding patients who require critical transfusions, especially during acute medical scenarios. This strategic expansion in leadership is expected to guide Hemanext towards further advancements in its impactful healthcare solutions.